Roivant Sciences (ROIV) Liabilities and Shareholders Equity (2021 - 2026)

Roivant Sciences' Liabilities and Shareholders Equity history runs 6 years deep, the most recent figure standing at $5.7 billion for Q1 2026.

• Quarterly Liabilities and Shareholders Equity rose 5.0% year-over-year to $5.7 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $21.0 billion (down 12.13% YoY) and the FY2026 annual result came in at $5.7 billion, up 5.0% from the prior year.
• Liabilities and Shareholders Equity was $5.7 billion for Q1 2026 at Roivant Sciences, up from $5.2 billion in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $7.3 billion in Q4 2023 and bottomed at $2.1 billion in Q3 2023.
• A 5-year average of $4.5 billion and a median of $5.1 billion in 2025 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity fell 28.6% — and 2023, when it soared 231.95%.
• Roivant Sciences' Liabilities and Shareholders Equity stood at $2.2 billion in 2022, then surged by 231.95% to $7.3 billion in 2023, then decreased by 20.79% to $5.8 billion in 2024, then decreased by 9.79% to $5.2 billion in 2025, then advanced by 9.25% to $5.7 billion in 2026.
• Business Quant data shows ROIV's Liabilities and Shareholders Equity at $5.7 billion in Q1 2026, $5.2 billion in Q4 2025, and $5.1 billion in Q3 2025.